Cosentyx (secukinumab) is a biologic medication used to treat various inflammatory conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. The dosage of Cosentyx is dependent on the condition being treated, the patient's weight, and their response to treatment.

According to Drug Patent Watch [1], the recommended starting dose for Cosentyx is 300 mg, administered subcutaneously in divided doses over two weeks. After the initial dose, the recommended maintenance dose is 300 mg once every four weeks. However, the dosage can be adjusted based on the patient's response to treatment and their individual needs.

Medscape [2] reports that the recommended dose of Cosentyx for psoriasis and psoriatic arthritis is 300 mg subcutaneously at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks. The recommended dose for ankylosing spondylitis is 150 mg subcutaneously at weeks 0, 1, 2, 3, and 4, followed by 150 mg every 4 weeks.

A study published in the Journal of Clinical and Aesthetic Dermatology [3] found that the dose of Cosentyx can be adjusted based on the patient's response to treatment. In the study, patients with moderate to severe plaque psoriasis were treated with Cosentyx for 52 weeks. The dosage was increased to 450 mg for patients who did not achieve a 75% improvement in their psoriasis after 12 weeks of treatment.

In conclusion, the dosage of Cosentyx can be adjusted based on the patient's response to treatment and their individual needs. The recommended starting dose and maintenance dose depend on the condition being treated, and the patient's weight. However, the dosage can be increased or decreased as needed to achieve the desired therapeutic effect.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://reference.medscape.com/drug/cosentyx-secukinumab-999964
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031589/